MedTrace Logo

Study to Assess the Safety, Tolerability, and Effects of CHI-202 to Support Recovery From Physical Activity

NCT05026164 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2022-02-16

No results posted yet for this study

Summary

The study is designed as a proof of concept, single-center, randomized, double-blind, placebo controlled study to assess the safety and efficacy of CHI-202 (cannabinoids and other ingredients) compared to placebo in the treatment of Delayed Onset Muscle Soreness (DOMS).

Conditions

  • Delayed Onset Muscle Soreness (DOMS)

Interventions

DIETARY_SUPPLEMENT

CHI-202

Blend of cannabinoids \& other ingredients

DIETARY_SUPPLEMENT

CHI-101

Placebo

Sponsors & Collaborators

  • Canopy Growth Corporation

    lead INDUSTRY

Principal Investigators

  • Erica Peters, PhD · Canopy Growth Corporation

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-12-13
Primary Completion
2022-02-04
Completion
2022-02-04

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05026164 on ClinicalTrials.gov